sacituzumab govitecan-hziy Apr 29, 2022 Gilead Sciences More Than Doubles Q1 Trodelvy Sales Mar 7, 2022 Gilead to Pursue Expanded Breast Cancer Indication for Trodelvy Following Phase III Data Feb 2, 2022 Gilead Sciences Q4 Cell Therapy Sales Increase 47 Percent Dec 8, 2021 AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS Nov 23, 2021 European Commission Approves Gilead's Trodelvy for Metastatic TNBC Oct 29, 2021 Gilead Sciences Q3 CAR T-Cell Therapy Sales Increase 51 Percent Oct 15, 2021 CHMP Recommends Gilead's Trodelvy for Pretreated TNBC Jul 30, 2021 Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent Dec 11, 2020 Gilead's Trodelvy Benefits TNBC Patients Regardless of Trop-2 Expression, BRCA1/2 Status Premium Nov 4, 2020 Immunomedics' Trodelvy Enters Phase II Triple-Negative Breast Cancer Trial in China Sep 20, 2020 ESMO Studies Present New Treatment Options for Advanced Triple-Negative Breast Cancer Premium Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
